abelacimab

Novartis’s $925M Anthos Acquisition Brings Back Cardio Drug That Stops Blood Clots

The Anthos Therapeutics acquisition represents a homecoming for its drug abelacimab, which originated in Novartis’s labs. The antibody offers the potential to prevent blood clots without the bleeding risks associated with currently available anticoagulants.

By Frank Vinluan

BioPharma

Anthos receives FDA’s Fast Track designation for a drug candidate targeting patients with AFib

This is the second Fast Track designation Anthos has received for abelacimab in less than two months. The therapeutic is also the first Factor XI inhibitor to start enrolling patients in Phase 3 trials.

By Marissa Plescia

The Top EAP Companies for Mental Health Support

Employee assistance programs have become essential tools for organizations aiming to address mental health challenges, reduce burnout and foster healthier workplaces.

By AllOne Health

Discover the Most Effective Aquatic Therapy Programs in Chicago Suburbs

Incorporating aquatic therapy can enhance patient outcomes and shorten recovery times for health care professionals. In the Chicago suburbs, the demand for such programs is rising.

By FYZICAL Therapy & Balance Centers

Rethinking The Entry Point to Healthcare in America: Collaboration in Communities

Healthcare in the U.S. today exists in a complex, fragmented and costly system, and the people this system is designed for deserve a holistic approach to best address their individual health needs.

By Dr. Jeff Giullian - DaVita, & Dr. Gloria Winters - YMCA of the USA